Literature DB >> 2323521

Effect of loxiglumide on gallbladder contractile response to cerulein and food in humans.

A Malesci1, C De Fazio, S Festorazzi, C Bonato, A Valentini, M Tacconi, L Rovati, I Setnikar.   

Abstract

The present study investigated the effect of loxiglumide, a new selective cholecystokinin-receptor antagonist, on the gallbladder contractile responses to caerulein and to food in humans. In 6 healthy men, the gallbladder emptying driven by intravenous infusion of stepwise increasing doses of cerulein (10-80 ng/kg . h) and that induced by a 550-cal standard meal were monitored by ultrasonography. In both sets of experiments, the effect of loxiglumide was tested at various infusional rates against a control infusion of saline. An infusional rate of 2.5 mg/kg . h of loxiglumide abolished the gallbladder response even to maximal doses of cerulein, whereas a rate of 1.0 mg/kg . h counteracted the cholecystokinetic activity of cerulein up to the dose of 20 ng/kg . h. In postprandial experiments, the cholecystokinin antagonist dose-dependently inhibited the physiologic gallbladder contraction. The maximal gallbladder emptying, which always occurred 85 min after the meal, was 71.1% +/- 3.3% of basal volume in control studies, 39.2% +/- 1.8% during infusion of 2.5 mg/kg . h of loxiglumide, and 17.3% +/- 5.9% when 5.0 mg/kg . h were infused. A dose of 7.5 mg/kg . h of loxiglumide was able to prevent any postprandial emptying of the gallbladder. The present study shows that a selective cholecystokinin receptorial blockade competitively antagonizes cerulein-induced gallbladder contraction and dose-dependently inhibits postprandial gallbladder emptying.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2323521     DOI: 10.1016/0016-5085(90)90349-6

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  4 in total

Review 1.  Perspectives of CCK antagonists in pancreatic research and clinical use. Part I.

Authors:  L C Rovati
Journal:  Int J Pancreatol       Date:  1991-04

2.  Inhibitory effects of the cholecystokinin antagonist loxiglumide on pancreatic exocrine secretion and pancreatic growth in conscious rats.

Authors:  S Taguchi; G M Green; I Nakano; Y Hatta
Journal:  Int J Pancreatol       Date:  1992-04

3.  Enhancement of biliary carcinogenesis in hamsters by cholecystokinin.

Authors:  Y Ikematsu; T Tomioka; Y Tajima; T Tsunoda; T Kanematsu
Journal:  World J Surg       Date:  1995 Nov-Dec       Impact factor: 3.352

4.  Expression of receptors for gut peptides in human pancreatic adenocarcinoma and tumour-free pancreas.

Authors:  C Tang; I Biemond; G J Offerhaus; W Verspaget; C B Lamers
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.